Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study

Bipolar Disorders

Volumn 9, Issue 6, 2007, Pages 561-570

  Zarate Jr , Carlos A ^a,b   Singh, Jaskaran B ^a   Carlson, Paul J ^a   Quiroz, Jorge ^a   Jolkovsky, Libby ^a   Luckenbaugh, David A ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b CRC   (United States)

Author keywords

Antimanic; Mania; Protein kinase C; Tamoxifen

Indexed keywords

LORAZEPAM; PLACEBO; PROTEIN KINASE C INHIBITOR; TAMOXIFEN;

ACUTE DISEASE; ADULT; ARTHRALGIA; ARTICLE; BIPOLAR MANIA; BONE PAIN; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION LOSS; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DREAMING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EFFECT SIZE; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HOT FLUSH; HUMAN; IRRITABILITY; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NOSE CONGESTION; PILOT STUDY; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SIDE EFFECT; SKIN IRRITATION; SUICIDAL IDEATION; TASTE; TENSION; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ACUTE DISEASE; ADOLESCENT; ADULT; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROTEIN KINASE C; PSYCHIATRIC STATUS RATING SCALES; SIGNAL TRANSDUCTION; TAMOXIFEN; TREATMENT OUTCOME;

EID: 34548403443     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2007.00530.x     Document Type: Article

References (44)

1. Keck PE Jr. The management of acute mania. BMJ 2003; 327: 1002-1003.
2. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006; 11: 227-240.
3. Evins AE, Demopulos C, Nierenberg A, Culhane MA, Eisner L, Sachs G. A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disord 2006; 8: 75-80.
4. Manji HK, Zarate CA. Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: Implications for the development of improved therapeutics. Mol Psychiatry 2002; 7 (Suppl. 1): 1-7.
5. Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. Mol Interv 2004; 4: 259-272.
6. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38: 157-160.
7. Manji HK, Lenox RH. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999; 46: 1328-1351.
8. Browman KE, Kantor L, Richardson S, Badiani A, Robinson TE, Gnegy ME. Injection of the protein kinase C inhibitor Ro31-8220 into the nucleus accumbens attenuates the acute response to amphetamine: Tissue and behavioral studies. Brain Res 1998; 814: 112-119.
9. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 1994; 63: 2361-2364.
10. Kantor L, Gnegy ME. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther 1998; 284: 592-598.
11. Steketee JD. Injection of the protein kinase inhibitor H7 into the A10 dopamine region blocks the acute responses to cocaine: Behavioral and in vivo microdialysis studies. Neuropharmacology 1993; 32: 1289-1297.
12. Jope RS. Anti-bipolar therapy: Mechanism of action of lithium. Mol Psychiatry 1999; 4: 117-128.
13. Baum AE, Akula N, Cabanero M et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2007; in press.
14. Young LT, Wang JF, Woods CM, Robb JC. Platelet protein kinase C alpha levels in drug-free and lithium-treated subjects with bipolar disorder. Neuropsychobiology 1999; 40: 63-66.
15. Friedman E, Wang HY, Levinson D, Connell TA, Singh H. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 1993; 33: 520-525.
16. Manji HK, Etcheberrigaray R, Chen G, Olds JL. Lithium decreases membrane-associated protein kinase C in hippocampus: Selectivity for the alpha isozyme. J Neurochem 1993; 61: 2303-2310.
17. Hahn CG, Friedman E. Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord 1999; 1: 81-86.
18. Manji HK, Bersudsky Y, Chen G, Belmaker RH, Potter WZ. Modulation of protein kinase C isozymes and substrates by lithium: The role of myo-inositol. Neuropsychopharmacology 1996; 15: 370-381.
19. Lenox RH, Watson DG, Patel J, Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992; 570: 333-340.
20. Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: Potentiation by muscarinic receptor activation. J Neurochem 1996; 67: 767-777.
21. Wang HY, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 1996; 40: 568-575.
22. Giambalvo CT. Protein kinase C and dopamine transport -1. Effects of amphetamine in vivo. Neuropharmacology 1992; 31: 1201-1210.
23. Giambalvo CT. Protein kinase C and dopamine transport -2. Effects of amphetamine in vitro. Neuropharmacology 1992; 31: 1211-1222.
24. Steketee JD. Intra-A10 injection of H7 blocks the development of sensitization to cocaine. Neuroreport 1994; 6: 69-72.
25. Einat H, Yuan PX, Szabo ST, Dogra S, Manji HK. Protein kinase C inhibition antagonizes several facets of manic-like behaviors: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007; in press.
26. Birnbaum SG, Yuan PX, Wang M et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 2004; 306: 882-884.
27. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 1994; 31: 41-52.
28. Horgan K, Cooke E, Hallett MB, Mansel RE. Inhibition of protein kinase C-mediated signal transduction by tamoxifen. Importance for antitumour activity. Biochem Pharmacol 1986; 35: 4463-4465.
29. Couldwell WT, Weiss MH, DeGiorgio CM et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993; 32: 485-489; discussion 489-490.
30. Tang P, Roldan G, Brasher PM et al. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol 2006; 78: 311-316.
31. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000; 57: 95-97.
32. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
33. First MB, Spitzer RL, Gibbon M, Williams AR. Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: New York State Psychiatric Institute, Biometrics Research, 2001.
34. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
35. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): Rationale and standardization. Br J Psychiatry 1989; 7 (Suppl): 59-67.
36. Trump DL, Smith DC, Ellis PG et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 1992; 84: 1811-1816.
37. Chengappa KN, Baker RW, Shao L et al. Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord 2003; 5: 1-5.
38. Kulkarni J, Garland KA, Scaffidi A et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006; 31: 543-547.
39. Yildiz-Yesiloglu A. A Double-blind Placebo-controlled Trial of a Protein Kinase C Inhibitor: Tamoxifen in Treatment of Acute Mania. Paris, France: 19th European College of Neuropsychopharmacology, 2006, S.13.02.
40. Goldstein JA. Danazol and the rapid-cycling patient. J Clin Psychiatry 1986; 47: 153-154.
41. Chouinard G, Steinberg S, Steiner W. Estrogen-progesterone combination: another mood stabilizer? Am J Psychiatry 1987; 144: 826.
42. Lopez M, Lelliott CJ, Tovar S et al. Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes 2006; 55: 1327-1336.
43. Cathcart CK, Jones SE, Pumroy CS, Peters GN, Knox SM, Cheek JH. Clinical recognition and management of depression in node-negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 1993; 27: 277-281.
44. Legha SS. Tamoxifen in the treatment of breast cancer. Ann Intern Med 1988; 109: 219-228.